PL EN


2013 | 1 | 43-45
Article title

Metformina – nowe spojrzenie na stary lek

Content
Title variants
Languages of publication
PL
Abstracts
Contributors
References
  • Bailey CJ , Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care 1989; 12: 553–556.
  • Bailey CJ , Day C. Metformin: its botanical background. Pract Diab Inter 2004; 21(3): 115–174.
  • Werner E, Bell J. The preparation of methylguanidine, and of ß-dimethylguanidine by the interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides respectively. J Chem Soc Transactions 1922; 121: 1790–1795.
  • Werner E, Bell J. Über Biguanide. II . Die Blutzuckersenkende Wirkung der Biguanides. Ber Deuts Chem Gesellschaft 1929;62: 1398–1405.
  • Garcia EY . Fluamine, a new synthetic analgesic and antiflu drug. J Philippine Med Assoc 1950; 26: 287–293.
  • Stupniewski J, Chruściel T. N-dimethyl-di-guanide and its biological properties. Arch Immunol Ther Exp 1954; 2: 1–15.
  • Pollack MN . Insulin, insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr 2007; 86(3): 820–822.
  • Mor V, Unnikrishnan MK. 5’-adenosine monophosphate-activated protein kinase and the metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2011; 1(11), 3: 206–216.
  • Traczyk S, i wsp. Fizjologia człowieka z elementami fizjologii stosowanej i klinicznej. Warszawa: Wydawnictwo Lekarskie PZWL ; 2003: 381–383.
  • Boden G, Shulman GI . Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32(3): 14–23.
  • Abdul-Ghani MA . Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006; 29(5): 1130–1139.
  • Nathan DM , Davidson MB. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30(3): 753–759.
  • Bandurska-Stankiewicz E, i wsp. Stanowisko Polskiego Towarzystwa Badań nad Otyłością w kwestii stosowania metforminy u osób otyłych w stanach przedcukrzycowych. Endokrynol Otyłość Zab Przem Materii 2011; 7(2): 151–154.
  • Knowler WC . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 7(346),6: 393–403.
  • Goodwin PJ, Stambolic V. Obesity and insulin resistance in breast cancer – chemoprevention strategies with a focus on metformin.Breast 2011; 20(3): 31–35.
  • Ibarra-Drendall C, Dietze EC , Seewaldt VL. Metabolic syndrome and breast cancer risk: is there a role for metformin? Curr Breast Cancer Rep 2011; 3(3): 142–150.
  • Vakana E, Altman JK, Glaser H, et al. Antileukemic effects of AM PK activators on BCR -ABL expressing cells. Blood 2011; 118,24: 6399–6402.
  • Zhang ZJ. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2011; 34(10): 2323–2328.
  • Bo S, Ciccone G, Rosato R, et al. Cancer mortality reduction and metformin. A retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab 2011; (3): 1463.
  • Bodmer M, Becker C, Meier C, et al. Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol 2011; 123(2): 200–204.
  • Rattan R, Graham RP, Maguire JL , et al. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 2011; 13(5): 483–491.
  • Legro RS , Barnhart HX, Schlaff WD . Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356(6): 551–66.
  • De Leo V, Musacchio MC , Piomboni P, et al. The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. Eur J Obstet Gynecol Reprod Biol 2011; 157(1): 63–66.
  • Melemedjian OK, et al. Targeting adenosine monophosphate-activated protein kinase (AM PK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol Pain 2011; 21(7): 70.
  • Jeyabalan J, Shah M, Viollet B, et al. AM P-activated protein kinase pathway and bone metabolism. J Endocrinol 2011; 212(3):277–290.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.desklight-f8c794b8-b065-4166-8d60-b7d194d2fd21
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.